

**TORREYA INDIA:**  
A Global Investment Bank Serving  
Life Sciences Companies

REPRESENTATIVE TRANSACTIONS SINCE 2014

Over \$100 Billion  
in Deals Closed  
Across Nearly  
250 Assignments  
Since Inception

- Mergers & Acquisitions
- Pharmaceutical Asset Sales
- Capital Markets
- Licensing Deals


 Sale of Yargesa to  June 2018	 and affiliate Wintac, Limited acquired by  <b>\$190 million</b> Announced April 2018	 Sale to  January 2018	 Acquisition of API Plant from  December 2017
 Asset sale to  July 2017	 Sale of selected generic brands to  June 2017	 Acquisition of generics business of  <b>\$1.05 billion</b> June 2017	 Sale of stake of  <b>\$35 million</b> Joint Sell-Side Advisor May 2017
 Sale of India women's health business to  April 2017	 Sale of Intrathecal business to  <b>\$203 million</b> March 2017	 Sale of equity stake to  <b>\$33 million</b> November 2016	 Company sale to  <b>\$100+ million</b> December 2015

LEADING ADVISOR ON GLOBAL PHARMA TRANSACTIONS OF \$10 MILLION – \$1 BILLION,  
2015 – 2017

Personal Relationships,  
Operating Perspective,  
Life Sciences Focus  
Make Torrey a an  
Advisor of Choice  
in Europe

- Dedicated India team: five experienced professionals based in Mumbai
- Expertise in branded pharmaceuticals, generic pharmaceuticals, and life sciences
- Deep industry knowledge and executive-level relationships across sectors
- Serving clients' long-term interests: multiple transactions for many clients

% of pharma transactions with Torrey involvement<sup>1</sup>



<sup>1</sup> Global M&A and Asset-based deals over \$10 million in value, 2008 – 2017 where any financial advisor was used

**TORREYA.COM**  
NEW YORK | LONDON | MUMBAI

For more information, please contact +91 22-6127-1191

Securities offered in the United States are offered through Torrey Capital LLC, Member FINRA/SIPC.

In Europe, such services are offered through Torrey Partners (Europe) LLP, which is authorised and regulated by the UK Financial Conduct Authority.